HRP20151444T1 - Sredstva za lijeäśenje i postupci lijeäśenja dlbcl - Google Patents

Sredstva za lijeäśenje i postupci lijeäśenja dlbcl

Info

Publication number: HRP20151444T1
Authority: HR; Croatia
Prior art keywords: methods; treating dlbcl; dlbcl; treating
Prior art date: 2010-10-27

Application number

HRP20151444TT

Other languages

English (en)

Inventor

Gerhard Zugmaier

Dirk Nagorsen

Juergen Scheele

Original Assignee

Amgen Research (Munich) Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2015-12-31

Publication date

2016-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-31 Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh

2016-01-29 Publication of HRP20151444T1 publication Critical patent/HRP20151444T1/hr

2021-08-20 Publication of HRP20151444T4 publication Critical patent/HRP20151444T4/hr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

HRP20151444TT 2010-10-27 2015-12-31 Sredstva za liječenje i postupci liječenja dlbcl HRP20151444T4 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US40710710P	2010-10-27	2010-10-27
EP11787633.4A EP2632954B2 (en)	2010-10-27	2011-10-27	Means and methods for treating dlbcl
PCT/EP2011/068851 WO2012055961A1 (en)	2010-10-27	2011-10-27	Means and methods for treating dlbcl

Publications (2)

Publication Number	Publication Date
HRP20151444T1 true HRP20151444T1 (hr)	2016-01-29
HRP20151444T4 HRP20151444T4 (hr)	2021-08-20

Family

ID=45023802

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HRP20151444TT HRP20151444T4 (hr)	2010-10-27	2015-12-31	Sredstva za liječenje i postupci liječenja dlbcl
HRP20180882TT HRP20180882T1 (hr)	2010-10-27	2018-06-05	Sredstva za i postupci liječenja dlbcl

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HRP20180882TT HRP20180882T1 (hr)	2010-10-27	2018-06-05	Sredstva za i postupci liječenja dlbcl

Country Status (31)

Country	Link
US (2)	US9192665B2 (hr)
EP (3)	EP3412687B1 (hr)
JP (3)	JP5997168B2 (hr)
KR (1)	KR101889995B1 (hr)
CN (2)	CN105251003B (hr)
AU (1)	AU2011322581B2 (hr)
CA (1)	CA2815119C (hr)
CL (1)	CL2013001138A1 (hr)
CR (1)	CR20130245A (hr)
CY (3)	CY1117155T1 (hr)
DK (3)	DK2632954T4 (hr)
EA (1)	EA032139B1 (hr)
ES (3)	ES2675299T3 (hr)
HK (1)	HK1188229A1 (hr)
HR (2)	HRP20151444T4 (hr)
HU (3)	HUE037786T2 (hr)
IL (3)	IL225924A (hr)
LT (2)	LT3412687T (hr)
MA (1)	MA34619B1 (hr)
ME (1)	ME02311B (hr)
MY (1)	MY163057A (hr)
NZ (2)	NZ609201A (hr)
PL (3)	PL3018145T3 (hr)
PT (3)	PT2632954E (hr)
RS (3)	RS60094B1 (hr)
SG (1)	SG189869A1 (hr)
SI (3)	SI2632954T2 (hr)
SM (1)	SMT201600050B (hr)
TR (1)	TR201808019T4 (hr)
UA (1)	UA111175C2 (hr)
WO (1)	WO2012055961A1 (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006114115A1 (de)	2005-04-26	2006-11-02	Trion Pharma Gmbh	Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
PT2632954E (pt) *	2010-10-27	2016-02-03	Amgen Res Munich Gmbh	Meios e métodos para tratar dlbcl
ES2842937T3 (es) *	2010-11-10	2021-07-15	Amgen Res Munich Gmbh	Prevención de efectos adversos provocados por dominios de unión específicos de CD3
JO3529B1 (ar) *	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
KR102339240B1 (ko)	2013-10-15	2021-12-15	더 스크립스 리서치 인스티튜트	펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
WO2016154621A1 (en)	2015-03-26	2016-09-29	The California Institute For Biomedical Research	SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en)	2015-04-15	2018-12-05	The California Institute for Biomedical Research	Optimized pne-based chimeric receptor t cell switches and uses thereof
FI3298033T4 (fi)	2015-05-18	2023-09-22	Tcr2 Therapeutics Inc	Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
JP2019532017A (ja)	2016-07-14	2019-11-07	フレッドハッチンソンキャンサーリサーチセンター	がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
CN109715668A (zh)	2016-08-02	2019-05-03	T细胞受体治疗公司	用于使用融合蛋白进行tcr重编程的组合物和方法
GB2564823B8 (en)	2016-10-07	2022-06-29	Tcr2 Therapeutics Inc	Compositions and methods for TCR reprogramming using fusion proteins
JP7149935B2 (ja)	2016-10-19	2022-10-07	ザスクリプスリサーチインスティテュート	ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
JP7291396B2 (ja)	2016-11-22	2023-06-15	ティーシーアール２セラピューティクスインク．	融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US11865081B2 (en)	2017-12-29	2024-01-09	Virogin Biotech Canada Ltd.	Oncolytic viral delivery of therapeutic polypeptides
WO2020099513A1 (en) *	2018-11-13	2020-05-22	Lipoxen Technologies Limited	Glycopolysialylation of blinatumomab
EP3962490A4 (en) *	2019-05-03	2023-01-25	Kite Pharma, Inc.	CHEMERA ANTIGEN RECEPTOR IMMUNOTHERAPY ADMINISTRATION METHODS
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
JP2023551559A (ja) *	2020-12-04	2023-12-08	モルフォシス・アーゲー	抗ｃｄ１９併用療法
JP2024506831A (ja)	2021-01-28	2024-02-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイトカイン放出症候群を治療するための組成物及び方法
WO2023201226A1 (en)	2022-04-11	2023-10-19	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE243754T1 (de)	1987-05-21	2003-07-15	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung
JP4169478B2 (ja)	1998-04-21	2008-10-22	マイクロメットアーゲー	Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
CA2522586C (en)	2003-05-31	2017-02-21	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP2186527A1 (en)	2003-11-28	2010-05-19	Micromet AG	Compositions comprising polypeptides
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-CD19 antibodies and their applications in oncology
WO2006114115A1 (de) *	2005-04-26	2006-11-02	Trion Pharma Gmbh	Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CN101331151A (zh) *	2005-12-16	2008-12-24	麦克罗梅特股份公司	***性疾病的方式和方法
EP1976886B1 (en) *	2005-12-16	2014-12-17	Amgen Research (Munich) GmbH	Means and methods for the treatment of tumorous diseases
KR101456728B1 (ko)	2006-09-08	2014-10-31	메디뮨 엘엘씨	인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
AU2008234020B2 (en)	2007-04-03	2013-02-07	Amgen Research (Munich) Gmbh	Cross-species-specific CD3-epsilon binding domain
ME02363B (me) *	2008-11-07	2016-06-20	Amgen Res Munich Gmbh	Liječenje akutne limfoblastične leukemije
HUE025759T2 (en)	2009-10-27	2016-04-28	Amgen Res (Munich) Gmbh	Dosage system for administering CD19xCD3 bispecific antibody
PT2632954E (pt) *	2010-10-27	2016-02-03	Amgen Res Munich Gmbh	Meios e métodos para tratar dlbcl

2011
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en active Active
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en active Application Filing
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 SI SI201131489T patent/SI3018145T1/en unknown
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active IP Right Grant
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
2014
- 2014-02-14 HK HK14101399.9A patent/HK1188229A1/xx unknown
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
- 2015-12-31 HR HRP20151444TT patent/HRP20151444T4/hr unknown
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown

Also Published As

Publication number	Publication date
HUE037786T2 (hu)	2018-09-28
EP3018145B1 (en)	2018-04-04
EP3412687A1 (en)	2018-12-12
HRP20180882T1 (hr)	2018-07-27
KR101889995B1 (ko)	2018-08-20
EP2632954A1 (en)	2013-09-04
MY163057A (en)	2017-08-15
SMT201600050B (it)	2016-04-29
CY1117155T1 (el)	2017-04-05
JP2016164192A (ja)	2016-09-08
IL260774B (en)	2019-02-28
CY1120227T1 (el)	2018-12-12
CN103459425B (zh)	2015-11-25
SI2632954T2 (sl)	2021-11-30
AU2011322581B2 (en)	2015-04-23
NZ701715A (en)	2016-05-27
EP3412687B1 (en)	2020-03-18
TR201808019T4 (tr)	2018-06-21
JP6254220B2 (ja)	2017-12-27
HK1188229A1 (en)	2014-04-25
SI2632954T1 (sl)	2016-02-29
DK3412687T3 (da)	2020-05-11
EA201390387A1 (ru)	2013-10-30
SG189869A1 (en)	2013-06-28
CN105251003A (zh)	2016-01-20
US10696744B2 (en)	2020-06-30
AU2011322581A1 (en)	2013-05-09
HRP20151444T4 (hr)	2021-08-20
PL2632954T3 (pl)	2016-05-31
PT3018145T (pt)	2018-05-17
PL3018145T3 (pl)	2018-09-28
CR20130245A (es)	2013-09-20
US20130287778A1 (en)	2013-10-31
ES2675299T3 (es)	2018-07-10
UA111175C2 (uk)	2016-04-11
PT3412687T (pt)	2020-04-03
HUE048639T2 (hu)	2020-08-28
PL2632954T5 (pl)	2021-11-02
ME02311B (me)	2016-06-20
SI3018145T1 (en)	2018-08-31
KR20140019298A (ko)	2014-02-14
CL2013001138A1 (es)	2014-11-14
CN103459425A (zh)	2013-12-18
CN105251003B (zh)	2019-08-02
RS60094B1 (sr)	2020-05-29
RS54525B2 (sr)	2021-08-31
WO2012055961A1 (en)	2012-05-03
EA032139B1 (ru)	2019-04-30
RS54525B1 (en)	2016-06-30
DK2632954T4 (da)	2021-08-09
CA2815119A1 (en)	2012-05-03
RS57260B1 (sr)	2018-08-31
SI3412687T1 (sl)	2020-07-31
IL256110B (en)	2018-08-30
IL256110A (en)	2018-02-28
IL225924A0 (en)	2013-06-27
ES2563439T3 (es)	2016-03-15
EP2632954B2 (en)	2021-07-07
CY1123251T1 (el)	2021-10-29
PL3412687T3 (pl)	2020-07-27
NZ719768A (en)	2021-07-30
PT2632954E (pt)	2016-02-03
LT3018145T (lt)	2018-05-10
CA2815119C (en)	2023-01-10
JP2013540799A (ja)	2013-11-07
US20160208001A1 (en)	2016-07-21
US9192665B2 (en)	2015-11-24
JP5997168B2 (ja)	2016-09-28
NZ609201A (en)	2015-01-30
DK3018145T3 (en)	2018-05-28
IL225924A (en)	2017-12-31
ES2563439T5 (es)	2022-02-04
HUE027678T2 (en)	2016-11-28
ES2787044T3 (es)	2020-10-14
EP3018145A1 (en)	2016-05-11
MA34619B1 (fr)	2013-10-02
LT3412687T (lt)	2020-07-27
JP6522722B2 (ja)	2019-05-29
EP2632954B1 (en)	2015-11-25
DK2632954T3 (en)	2016-02-01
JP2018039838A (ja)	2018-03-15

Publication	Publication Date	Title
HRP20180882T1 (hr)	2018-07-27	Sredstva za i postupci liječenja dlbcl
EP2619715A4 (en)	2016-08-10	METHOD AND DEVICES FOR CONTEXT DEFINITION
PL2649391T3 (pl)	2017-10-31	Urządzenie do suszenia i sposoby suszenia
GB201003190D0 (en)	2010-04-14	Apparatus and method
ZA201303423B (en)	2015-06-24	Compositions and methods for treating myelofibrosis
ZA201304360B (en)	2014-02-26	Method and device for treating biomass
PT2627818T (pt)	2021-04-07	Método e disposição para tratamento de pasta
EP2533806A4 (en)	2013-08-07	METHODS AND MATERIALS FOR TREATING CANCER
GB201005885D0 (en)	2010-05-26	Apparatus and method
GB201003255D0 (en)	2010-04-14	Apparatus and method
GB201105826D0 (en)	2011-05-18	Apparatus and method
GB201021057D0 (en)	2011-01-26	Method and apparatus
EP2610715A4 (en)	2014-09-17	A CONTROL BALL BASED METHOD AND DEVICE FOR PRESSING POSITIONING
GB201011768D0 (en)	2010-08-25	Apparatus and methods for operation
GB201010290D0 (en)	2010-08-04	Apparatus and methods
GB201000806D0 (en)	2010-03-03	Apparatus and methods
GB201016993D0 (en)	2010-11-24	Apparatus and method
GB201012886D0 (en)	2010-09-15	Apparatus and method
GB201010399D0 (en)	2010-08-04	Apparatus and method
GB201010267D0 (en)	2010-08-04	Apparatus and method
GB201008082D0 (en)	2010-06-30	Apparatus and method
GB201003264D0 (en)	2010-04-14	Apparatus and method
GB201001459D0 (en)	2010-03-17	Apparatus and method
GB201001033D0 (en)	2010-03-10	Method and apparatus